European Respiratory Society guidelines on the diagnosis and treatment of chronic cough in adults and children

These guidelines incorporate the recent advances in chronic cough pathophysiology, diagnosis and treatment. The concept of cough hypersensitivity has allowed an umbrella term that explains the exquisite sensitivity of patients to external stimuli such a cold air, perfumes, smoke and bleach. Thus, adults with chronic cough now have a firm physical explanation for their symptoms based on vagal afferent hypersensitivity. Different treatable traits exist with cough variant asthma (CVA)/eosinophilic bronchitis responding to anti-inflammatory treatment and non-acid reflux being treated with promotility agents rather the anti-acid drugs. An alternative antitussive strategy is to reduce hypersensitivity by neuromodulation. Low-dose morphine is highly effective in a subset of patients with cough resistant to other treatments. Gabapentin and pregabalin are also advocated, but in clinical experience they are limited by adverse events. Perhaps the most promising future developments in pharmacotherapy are drugs which tackle neuronal hypersensitivity by blocking excitability of afferent nerves by inhibiting targets such as the ATP receptor (P2X3). Finally, cough suppression therapy when performed by competent practitioners can be highly effective. Children are not small adults and a pursuit of an underlying cause for cough is advocated. Thus, in toddlers, inhalation of a foreign body is common. Persistent bacterial bronchitis is a common and previously unrecognised cause of wet cough in children. Antibiotics (drug, dose and duration need to be determined) can be curative. A paediatric-specific algorithm should be used.

1. Song W.J., Chang Y.S., Faruqi S. et al. The global epidemiology of chronic cough in adults: a systematic review and meta-analysis. Eur. Respir. J. 2015; 45 (5): 1479–1481. DOI: 10.1183/09031936.00218714.

2. Chamberlain S.A., Garrod R., Douiri A. et al. The impact of chronic cough: a cross-sectional European survey. Lung. 2015; 193 (3): 401–408. DOI: 10.1007/s00408-015-9701-2.

3. Morice A.H., Jakes A.D., Faruqi S. et al. A worldwide survey of chronic cough: A manifestation of enhanced somatosensory response. Eur. Respir. J. 2014; 44 (5): 1149–1155. DOI: 10.1183/09031936.00217813.

4. Millqvist E. The airway sensory hyperreactivity syndrome. Pulm. Pharmacol. Ther. 2011; 24 (3): 263–266. DOI: 10.1016/j.pupt.2010.10.001.

5. Morice A.H., Millqvist E., Belvisi M.G. et al. Expert opinion on the cough hypersensitivity syndrome in respiratory medicine. Eur. Respir. J. 2014; 44 (5): 1132–1148. DOI: 10.1183/09031936.00218613.

6. Chang A.B. Pediatric cough: Children are not miniature adults. Lung. 2010; 188 (Suppl. 1): S33–40. DOI: 10.1007/s00408-009-9166-2.

7. Miravitlles M., Tonia T., Rigau D. et al. New era for European Respiratory Society clinical practice guidelines: Joining efficiency and high methodological standards. Eur. Respir. J. 2018; 51 (3): 1800221. DOI: 10.1183/13993003.00221-2018.

8. Song W.J., Chang Y.S., Faruqi S. et al. Defining chronic cough: a systematic review of the epidemiological literature. Allergy Asthma Immunol. Res. 2016; 8 (2): 146–155. DOI: 10.4168/aair.2016.8.2.146.

9. Morice A.H., Fontana G.A., Belvisi M.G. et al. ERS guidelines on the assessment of cough. Eur. Respir. J. 2007; 29 (6): 1256–1276. DOI: 10.1183/09031936.00101006.

10. Chang A.B., Glomb W.B. Guidelines for evaluating chronic cough in pediatrics: ACCP evidence-based clinical practice guidelines. Chest. 2006; 129 (1, Suppl.): S260–283. DOI: 10.1378/chest.129.1_suppl.260S.

11. Shields M.D., Bush A., Everard M.L. et al. BTS guidelines: Recommendations for the assessment and management of cough in children. Thorax. 2008; 63 (Suppl. 3): iii1–15. DOI: 10.1136/thx.2007.077370.

12. Morice A.H. Epidemiology of cough. Pulm. Pharmacol. Ther. 2002; 15 (3): 253–259. DOI: 10.1006/pupt.2002.0352.

13. Ford A.C., Forman D., Moayyedi P., Morice A.H. Cough in the community: a cross sectional survey and the relationship to gastrointestinal symptoms. Thorax. 2006; 61 (11): 975–979. DOI: 10.1136/thx.2006.060087.

14. Çolak Y., Nordestgaard B.G., Laursen L.C. et al. Risk factors for chronic cough among 14,669 individuals from the general population. Chest. 2017; 152 (3): 563–573. DOI: 10.1016/j.chest.2017.05.038.

15. Kang M.G., Song W.J., Kim H.J. et al. Point prevalence and epidemiological characteristics of chronic cough in the general adult population: the Korean National Health and Nutrition Examination Survey 2010–2012. Medicine (Baltimore). 2017; 96 (13): e6486. DOI: 10.1097/MD.0000000000006486.

16. Lätti A.M., Pekkanen J., Koskela. H.O. Defining the risk factors for acute, subacute and chronic cough: a cross-sectional study in a Finnish adult employee population. BMJ Open. 2018; 8 (7): e022950. DOI: 10.1136/bmjopen-2018-022950.

17. Kogan M.D., Pappas G., Yu S.M., Kotelchuck M. Over-the-counter medication use among US preschool-age children. JAMA. 1994; 272 (13): 1025–1030. DOI: 10.1001/jama.1994.03520130063034.

18. Singh D., Arora V., Sobti P.C. Chronic/recurrent cough in rural children in Ludhiana, Punjab. Indian Pediatr. 2002; 39 (1): 23–29. Available at: https://indianpediatrics.net/jan2002/jan-23-29.htm

19. Leonardi G.S., Houthuijs D., Nikiforov B. et al. Respiratory symptoms, bronchitis and asthma in children of Central and Eastern Europe. Eur. Respir. J. 2002; 20 (4): 890–898. DOI: 10.1183/09031936.02.00260802.

20. Pan G., Zhang S., Feng Y. et al. Air pollution and children’s respiratory symptoms in six cities of Northern China. Respir. Med. 2010; 104 (12): 1903–1911. DOI: 10.1183/09031936.02.00260802.

21. Dales R.E., White J., Bhumgara C., McMullen E. Parental reporting of childrens’ coughing is biased. Eur. J. Epidemiol. 1997; 13 (5): 541–545. DOI: 10.1023/a:1007311912777.

22. French C.L., Irwin R.S., Curley F.J., Krikorian C.J. Impact of chronic cough on quality of life. Arch. Intern. Med. 1998; 158 (15): 1657–1661. DOI: 10.1001/archinte.158.15.1657.

23. Raj A.A., Birring S.S. Clinical assessment of chronic cough severity. Pulm. Pharmacol. Ther. 2007; 20 (4): 334–337. DOI: 10.1016/j.pupt.2006.10.002.

24. French C.L., Crawford S.L., Bova C., Irwin R.S. Change in psychological, physiological, and situational factors in adults after treatment of chronic cough. Chest. 2017; 152 (3): 547–562. DOI: 10.1016/j.chest.2017.06.024.

25. French C.T., Irwin R.S., Fletcher K.E., Adams T.M. Evaluation of cough-specific quality-of-life questionnaire. Chest. 2002; 121 (4): 1123– 1131. DOI: 10.1378/chest.121.4.1123.

26. Birring S.S., Prudon B., Carr A.J. et al. Development of a symptom specific health status measure for patients with chronic cough: Leicester Cough Questionnaire (LCQ). Thorax. 2003; 58 (4): 339–343. DOI: 10.1136/thorax.58.4.339.

27. Morice A.H., Menon M.S., Mulrennan S.A. et al. Opiate therapy in chronic cough. Am. J. Respir. Crit. Care Med. 2007; 175 (4): 312–315. DOI: 10.1164/rccm.200607-892OC.

28. Marchant J.M., Newcombe P.A., Juniper E.F. et al. What is the burden of chronic cough for families? Chest. 2008; 134 (2): 303–309. DOI: 10.1378/chest.07-2236.

29. Kantar A., Bernardini R., Paravati F. et al. Chronic cough in preschool children. Early Hum. Dev. 2013; 89 (Suppl. 3): S19–24. DOI: 10.1016/j.earlhumdev.2013.07.018.

30. Luyt D.K., Burton P.R., Simpson H. Epidemiological study of wheeze, doctor diagnosed asthma, and cough in preschool children in Leicestershire. BMJ. 1993; 306 (6889): 1386–1390. DOI: 10.1136/bmj.306.6889.1386.

31. Chang A.B., Landau L.I., Van Asperen P.P. et al. Cough in children: definitions and clinical evaluation. Med. J. Aust. 2006; 184 (8): 398–403. DOI: 10.5694/j.1326-5377.2006.tb00290.x.

32. Demoulin-Alexikova S., Plevkova J., Mazurova L. et al. Impact of air pollution on age and gender related increase in cough reflex sensitivity of healthy children in Slovakia. Front. Physiol. 2016; 7: 54. DOI: 10.3389/fphys.2016.00054.

33. Ebihara S., Ebihara T., Kohzuki M. Effect of aging on cough and swallowing reflexes: implications for preventing aspiration pneumonia. Lung. 2012; 190: 29–33. DOI: 10.1007/s00408-011-9334-z.

34. Canning B.J. Functional implications of the multiple afferent pathways regulating cough. Pulm. Pharmacol. Ther. 2011; 24 (3): 295–299. DOI: 10.1016/j.pupt.2011.01.008.

35. Belvisi M.G., Birrell M.A., Khalid S. et al. Neurophenotypes in airway diseases. Insights from translational cough studies. Am. J. Respir. Crit. Care Med. 2016; 193: 1364–1372. DOI: 10.1164/rccm.201508-1602OC.

36. Bonvini S.J., Birrell M.A., Grace M.S. et al. Transient receptor potential cation channel, subfamily V, member 4 and airway sensory afferent activation: role of adenosine triphosphate. J. Allergy Clin. Immunol. 2016; 138 (1): 249–261. DOI: 10.1016/j.jaci.2015.10.044.

37. Morice A.H., Kitt M.M., Ford A.P. et al. The effect of gefapixant, a P2X3 antagonist, on cough reflex sensitivity: a randomised placebo-controlled study. Eur. Respir. J. 2019; 54 (1): 1900439. DOI: 10.1183/13993003.00439-2019.

38. Mazzone S.B., Farrell M.J. Heterogeneity of cough neurobiology: clinical implications. Pulm. Pharmacol. Ther. 2019; 55: 62–66. DOI: 10.1016/j.pupt.2019.02.002.

39. Mazzone S.B., Chung K.F., McGarvey L. The heterogeneity of chronic cough: a case for endotypes of cough hypersensitivity. Lancet Respir. Med. 2018; 6: 636–646. DOI: 10.1016/S2213-2600(18)30150-4.

40. Lund S., Walford H.H., Doherty T.A. Type 2 innate lymphoid cells in allergic disease. Curr. Immunol. Rev. 2013; 9: 214–221. DOI: 10.2174/1573395510666140304235916.

41. Brightling C.E., Ward R., Goh K.L. et al. Eosinophilic bronchitis is an important cause of chronic cough. Am. J. Respir. Crit. Care Med. 1999; 160: 406–410. DOI: 10.1164/ajrccm.160.2.9810100.

42. Burke J.M., Jackson W., Morice A.H. The role of high resolution oesophageal manometry in occult respiratory symptoms. Respir. Med. 2018; 138: 47–49. DOI: 10.1016/j.rmed.2018.03.027.

43. Ando A., Smallwood D., McMahon M. et al. Neural correlates of cough hypersensitivity in humans: evidence for central sensitisation and dysfunctional inhibitory control. Thorax. 2016; 71 (4): 323–329. DOI: 10.1136/thoraxjnl-2015-207425.

44. Chung K.F., McGarvey L., Mazzone S.B. Chronic cough as a neuropathic disorder. Lancet Respir. Med. 2013; 1: 412–422. DOI: 10.1016/S2213-2600(13)70043-2.

45. Spring P.J., Kok C., Nicholson G.A. et al. Autosomal dominant hereditary sensory neuropathy with chronic cough and gastro-oesophageal reflux: clinical features in two families linked to chromosome 3p22-p24. Brain. 2005; 128 (Pt 12): 2797–2810. DOI: 10.1093/brain/awh653.

46. Song W.J., Kim H.J., Shim J.S. et al. Diagnostic accuracy of fractional exhaled nitric oxide measurement in predicting cough-variant asthma and eosinophilic bronchitis in adults with chronic cough: a systematic review and meta-analysis. J. Allergy Clin. Immunol. 2017; 140 (3): 701–709. DOI: 10.1016/j.jaci.2016.11.037.

47. Mathur S.K., Fichtinger P.S., Evans M.D. et al. Variability of blood eosinophil count as an asthma biomarker. Ann. Allergy Asthma Immunol. 2016; 117 (5): 551–553. DOI: 10.1016/j.anai.2016.08.010.

48. Hamad G.A., Cheung W., Crooks M.G., Morice A.H. Eosinophils in COPD: how many swallows make a summer? Eur. Respir. J. 2018; 51 (1): 1702177. DOI: 10.1183/13993003.02177-2017.

49. Wagener A.H., de Nijs S.B., Lutter R. et al. External validation of blood eosinophils, FE(NO) and serum periostin as surrogates for sputum eosinophils in asthma. Thorax. 2015; 70 (2): 115–120. DOI: 10.1136/thoraxjnl-2014-205634.

50. Magnussen H., Disse B., Rodriguez-Roisin R. et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N. Engl. J. Med. 2014; 371 (14): 1285–1294. DOI: 10.1056/NEJMoa1407154.

51. Corrao W.M., Braman S.S., Irwin R.S. Chronic cough as the sole presenting manifestation of bronchial asthma. N. Engl. J. Med. 1979; 300: 633–637. DOI: 10.1056/NEJM197903223001201.

52. Gibson P.G., Dolovich J., Denburg J. et al. Chronic cough: eosinophilic bronchitis without asthma. Lancet. 1989; 1 (8651): 1346–1348. DOI: 10.1016/s0140-6736(89)92801-8.

53. Irwin R.S., French C.L., Curley F.J. et al. Chronic cough due to gastroesophageal reflux. Clinical, diagnostic, and pathogenetic aspects. Chest. 1993; 104 (5): 1511–1517. DOI: 10.1378/chest.104.5.1511.

54. Kahrilas P.J., Howden C.W., Hughes N., Molloy-Bland M. Response of chronic cough to acid-suppressive therapy in patients with gastroesophageal reflux disease. Chest. 2013; 143 (3): 605–612. DOI: 10.1378/chest.12-1788.

55. Patterson N., Mainie I., Rafferty G. et al. Nonacid reflux episodes reaching the pharynx are important factors associated with cough. J. Clin. Gastroenterol. 2009; 43 (5): 414–419. DOI: 10.1097/MCG.0b013e31818859a3.

56. Morice A.H., Faruqi S., Wright C.E. et al. Cough hypersensitivity syndrome: a distinct clinical entity. Lung. 2011; 189 (1): 73–79. DOI: 10.1007/s00408-010-9272-1.

57. Belafsky P.C., Postma G.N., Koufman J.A. Validity and reliability of the reflux symptom index (RSI). J. Voice. 2002; 16 (2): 274–277. DOI: 10.1016/s0892-1997(02)00097-8.

58. Everett C.F., Morice A.H. Clinical history in gastroesophageal cough. Respir. Med. 2007; 101 (2): 345–348. DOI: 10.1016/j.rmed.2006.05.006.

59. Pacheco A., Faro V., Cobeta I. et al. Gastro-oesophageal reflux, eosinophilic airway inflammation and chronic cough. Respirology. 2011; 16 (6): 994–999. DOI: 10.1111/j.1440-1843.2011.02010.x.

60. Irwin R.S., Baumann M.H., Bolser D.C. et al. Diagnosis and management of cough executive summary: ACCP evidence-based clinical practice guidelines. Chest. 2006; 129 (1, Suppl.): S1–23. DOI: 10.1378/chest.129.1_suppl.1S.

61. Dicpinigaitis P.V., Morice A.H., Birring S.S. et al. Antitussive drugs – past, present, and future. Pharmacol. Rev. 2014; 66 (2): 468–512. DOI: 10.1124/pr.111.005116.

62. Morice A.H., Lowry R., Brown M.J. et al. Angiotensin – converting enzyme and the cough reflex. Lancet. 1987; 2 (8568): 1116–1118. DOI: 10.1016/s0140-6736(87)91547-9.

63. Yeo W.W., Chadwick I.G., Kraskiewicz M. et al. Resolution of ACE inhibitor cough: changes in subjective cough and responses to inhaled capsaicin, intradermal bradykinin and substance-P. Br. J. Clin. Pharmacol. 1995; 40 (5): 423–429.

64. Fahim A., Morice A.H. Heightened cough sensitivity secondary to latanoprost. Chest. 2009; 136 (5): 1406–1407. DOI: 10.1378/chest.09-0070.

65. Chang A.B., Oppenheimer J.J., Weinberger M.M. et al. Use of management pathways or algorithms in children with chronic cough: CHEST guideline and expert panel report. Chest 2017; 151 (4): 875–883. DOI: 10.1016/j.chest.2016.12.025.

66. Kantar A. Update on pediatric cough. Lung. 2016; 194 (1): 9–14. DOI: 10.1007/s00408-015-9815-6.

67. Chang A.B., Robertson C.F., van Asperen P.P. et al. A cough algorithm for chronic cough in children: a multicenter, randomized controlled study. Pediatrics. 2013; 131 (5): e1576–1583. DOI: 10.1542/peds.2012-3318.

68. Taussig L.M., Smith S.M., Blumenfeld R. Chronic bronchitis in childhood: what is it? Pediatrics. 1981; 67 (1): 1–5.

69. Kantar A., Chang A.B., Shields M.D. et al. ERS statement on protracted bacterial bronchitis in children. Eur. Respir. J. 2017; 50 (2): 1602139. DOI: 10.1183/13993003.02139-2016.

70. Wurzel D.F., Marchant J.M., Yerkovich S.T. et al. Protracted bacterial bronchitis in children: natural history and risk factors for bronchiectasis. Chest. 2016; 150 (5): 1101–1108. DOI: 10.1016/j.chest.2016.06.030

71. Chang A.B., Oppenheimer J.J., Weinberger M. et al. Children with chronic wet or productive cough - treatment and investigations: a systematic review. Chest. 2016; 149 (1): 120–142. DOI: 10.1378/chest.15-2065.

72. Haydour Q., Alahdab F., Farah M. et al. Management and diagnosis of psychogenic cough, habit cough, and tic cough: a systematic review. Chest. 2014; 146 (2): 355–372. DOI: 10.1378/chest.14-0795.

73. Vertigan A.E. Somatic cough syndrome or psychogenic cough – what is the difference? J. Thorac. Dis. 2017; 9: 831–838. DOI: 10.21037/jtd.2017.03.119.

74. McGarvey L., Gibson P.G. What is chronic cough? Terminology. J. Allergy Clin. Immunol. Pract. 2019; 7: 1711–1714. DOI: 10.1016/j.jaip.2019.04.012.

75. van Manen M.J.G., Birring S.S., Vancheri C. et al. Effect of pirfenidone on cough in patients with idiopathic pulmonary fibrosis. Eur. Respir. J. 2017; 50 (4): 1701157. DOI: 10.1183/13993003.01157-2017.

76. Birring S.S., Wijsenbeek M.S., Agrawal S. et al. A novel formulation of inhaled sodium cromoglicate (PA101) in idiopathic pulmonary fibrosis and chronic cough: a randomised, double-blind, proof-of-concept, phase 2 trial. Lancet Respir. Med. 2017; 5 (10): 806–815. DOI: 10.1016/S2213-2600(17)30310-7.

77. Freund K.M., Belanger A.J., D’Agostino R.B., Kannel W.B. The health risks of smoking. The Framingham Study: 34 years of follow-up. Ann. Epidemiol. 1993; 3 (4): 417–424. DOI: 10.1016/1047-2797(93)90070-k.

78. Sumner H., Woodcock A., Kolsum U. et al. Predictors of objective cough frequency in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2013; 187 (9): 943–949. DOI: 10.1164/rccm.201211-2000OC.

79. Millqvist E., Bende M. Capsaicin cough sensitivity is decreased in smokers. Respir. Med. 2001; 95 (1): 19–21. DOI: 10.1053/rmed.2000.0965.

80. Dicpinigaitis P.V. Cough reflex sensitivity in cigarette smokers. Chest. 2003; 123 (3): 685–688. DOI: 10.1378/chest.123.3.685.

81. Dicpinigaitis P.V., Lee Chang A., Dicpinigaitis A.J., Negassa A. Effect of e-cigarette use on cough reflex sensitivity. Chest. 2016; 149 (1): 161–165. DOI: 10.1378/chest.15-0817.

82. Cummings K.M., Giovino G., Jaen C.R., Emrich L.J. Reports of smoking withdrawal symptoms over a 21 day period of abstinence. Addict. Behav. 1985; 10 (4): 373–381. DOI: 10.1016/0306-4603(85)90034-6.

83. Hajek P., Phillips-Waller A., Przulj D. et al. A randomized trial of e-cigarettes versus nicotine-replacement therapy. N. Engl. J. Med. 2019; 380 (7): 629–637. DOI: 10.1056/NEJMoa1808779.

84. Nordin S., Palmquist E., Bende M., Millqvist E. Normative data for the chemical sensitivity scale for sensory hyperreactivity: the vasterbotten environmental health study. Int. Arch. Occup. Environ. Health. 2013; 86 (7): 749–753. DOI: 10.1007/s00420-012-0812-2.

85. Kastelik J.A., Aziz I., Ojoo J.C. et al. Investigation and management of chronic cough using a probability-based algorithm. Eur. Respir. J. 2005; 25 (2): 235–243. DOI: 10.1183/09031936.05.00140803.

86. McGarvey L.P., Heaney L.G., Lawson J.T. et al. Evaluation and outcome of patients with chronic non-productive cough using a comprehensive diagnostic protocol. Thorax. 1998; 53 (9): 738–743. DOI: 10.1136/thx.53.9.738.

87. French C.T., Diekemper R.L., Irwin R.S. et al. Assessment of intervention fidelity and recommendations for researchers conducting studies on the diagnosis and treatment of chronic cough in the adult: CHEST guideline and expert panel report. Chest. 2015; 148 (1): 32–54. DOI: 10.1378/chest.15-0164.

88. Berrington de Gonzalez A., Mahesh M., Kim K.P. et al. Projected cancer risks from computed tomographic scans performed in the United States in 2007. Arch. Intern. Med. 2009; 169 (22): 2071–2077. DOI: 10.1001/archinternmed.2009.440.

89. Brenner D.J., Hall E.J. Computed tomography – an increasing source of radiation exposure. N. Engl. J. Med. 2007; 357 (22): 2277–2284. DOI: 10.1056/NEJMra072149.

90. Sadeghi M.H., Wright C.E., Hart S. et al. Phenotyping patients with chronic cough: evaluating the ability to predict the response to anti-inflammatory therapy. Ann. Allergy Asthma Immunol. 2018; 120 (3): 285–291. DOI: 10.1016/j.anai.2017.12.004.

91. Sadeghi M.H., Wright C.E., Hart S. et al. Does FeNO predict clinical characteristics in chronic cough? Lung. 2018; 196 (1): 59–64. DOI: 10.1007/s00408-017-0074-6.

92. Watanabe K., Shinkai M., Shinoda M. et al. Measurement of eNO with portable analyser might improve the management of persistent cough at primary care practice in Japan. Clin. Respir. J. 2016; 10 (3): 380–388. DOI: 10.1111/crj.12228.

93. Hahn P.Y., Morgenthaler T.Y., Lim K.G. Use of exhaled nitric oxide in predicting response to inhaled corticosteroids for chronic cough. Mayo Clin. Proc. 2007; 82 (11): 1350–1355. DOI: 10.4065/82.11.1350.

94. Prieto L., Ferrer A., Ponce S. et al. Exhaled nitric oxide measurement is not useful for predicting the response to inhaled corticosteroids in subjects with chronic cough. Chest. 2009; 136 (3): 816–822. DOI: 10.1378/chest.08-2942.

95. Doan T., Patterson R., Greenberger P.A. Cough variant asthma: usefulness of a diagnostic-therapeutic trial with prednisone. Ann. Allergy. 1992; 69 (6): 505–509.

96. Brightling C.E., Bradding P., Symon F.A. et al. Mast-cell infiltration of airway smooth muscle in asthma. N. Engl. J. Med. 2002; 346 (22): 1699–1705. DOI: 10.1056/NEJMoa012705.

97. Jia Y., Fang X., Zhu X. et al. IL-13+ type 2 innate lymphoid cells correlate with asthma control status and treatment response. Am. J. Respir. Cell Mol. Biol. 2016; 55: 675–683. DOI: 10.1165/rcmb.2016-0099OC.

98. Takemura M., Niimi A., Matsumoto H. et al. Clinical, physiological and anti-inflammatory effect of montelukast in patients with cough variant asthma. Respiration. 2012; 83 (4): 308–315. DOI: 10.1159/000332835.

99. Vertigan A.E., Kapela S.M., Kearney E.K., Gibson P.G. Laryngeal dysfunction in cough hypersensitivity syndrome: a cross-sectional observational study. J. Allergy Clin. Immunol. Pract. 2018; 6 (6): 2087–2095. DOI: 10.1016/j.jaip.2018.04.015.

100. O’Hara J., Jones N.S. “Post-nasal drip syndrome”: most patients with purulent nasal secretions do not complain of chronic cough. Rhinology. 2006; 44 (4): 270–273. Available at: https://www.rhinologyjournal.com/Abstract.php?id=594

101. Pratter M.R., Bartter T., Lotano R. The role of sinus imaging in the treatment of chronic cough in adults. Chest. 1999; 116 (5): 1287–1291. DOI: 10.1378/chest.116.5.1287.

102. Chaudhuri R., McMahon A.D., Thomson L.J. et al. Effect of inhaled corticosteroids on symptom severity and sputum mediator levels in chronic persistent cough. J. Allergy Clin. Immunol. 2004; 113 (6): 1063–1070. DOI: 10.1016/j.jaci.2004.03.019.

103. Boulet L.P., Milot J., Boutet M. et al. Airway inflammation in nonasthmatic subjects with chronic cough. Am. J. Respir. Crit. Care Med. 1994; 149 (2, Pt 1): 482–489. DOI: 10.1164/ajrccm.149.2.8306050.

104. Pizzichini M.M., Pizzichini E., Parameswaran K. et al. Nonasthmatic chronic cough: no effect of treatment with an inhaled corticosteroid in patients without sputum eosinophilia. Can. Respir. J. 1999; 6 (4): 323–330. DOI: 10.1155/1999/434901.

105. Engel T., Heinig J.H., Madsen O. et al. A trial of inhaled budesonide on airway responsiveness in smokers with chronic bronchitis. Eur. Respir. J. 1989; 2 (10): 935–939. Available at: https://erj.ersjournals.com/content/erj/2/10/935.full.pdf

106. Wesseling G.J., Quaedvlieg M., Wouters E.F. Inhaled budesonide in chronic bronchitis. Effects on respiratory impedance. Eur. Respir. J. 1991; 4 (9): 1101–1105. Available at: https://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.915.9499&rep=rep1&type=pdf

107. Paggiaro P.L., Dahle R., Bakran I. et al. Multicentre randomised placebocontrolled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. International COPD study group. Lancet. 1998; 351 (9105): 773–780. DOI: 10.1016/s0140-6736(97)03471-5.

108. Calverley P., Pauwels R., Vestbo J. et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2003; 361 (9356): 449–456. DOI: 10.1016/S0140-6736(03)12459-2.

109. Davies M.J., Fuller P., Picciotto A., McKenzie S.A. Persistent nocturnal cough: randomised controlled trial of high dose inhaled corticosteroid. Arch. Dis. Child. 1999; 81 (1): 38–44. DOI: 10.1136/adc.81.1.38.

110. Chang A.B., Phelan P.D., Carlin J.B. et al. A randomised, placebo controlled trial of inhaled salbutamol and beclomethasone for recurrent cough. Arch. Dis. Child. 1998; 79 (1): 6–11. DOI: 10.1136/adc.79.1.6.

111. Dicpinigaitis P.V., Dobkin J.B., Reichel J. Antitussive effect of the leukotriene receptor antagonist zafirlukast in subjects with cough-variant asthma. J. Asthma. 2002; 39 (4): 291–297. DOI: 10.1081/jas120002285.

112. Spector S.L., Tan R.A. Effectiveness of montelukast in the treatment of cough variant asthma. Ann. Allergy Asthma Immunol. 2004; 93 (3): 232–236. DOI: 10.1016/S1081-1206(10)61493-7.

113. Kita T., Fujimura M., Ogawa H. et al. Antitussive effects of the leukotriene receptor antagonist montelukast in patients with cough variant asthma and atopic cough. Allergol. Int. 2010; 59 (2): 185–192. DOI: 10.2332/allergolint.09-OA-0112.

114. Benard B., Bastien V., Vinet B. et al. Neuropsychiatric adverse drug reactions in children initiated on montelukast in real-life practice. Eur. Respir. J. 2017; 50 (2): 1700148. DOI: 10.1183/13993003.00148-2017.

115. Faruqi S., Molyneux I.D., Fathi H. et al. Chronic cough and esomeprazole: a double-blind placebo-controlled parallel study. Respirology. 2011; 16 (7): 1150–1156. DOI: 10.1111/j.1440-1843.2011.02014.x.

116. Shaheen N.J., Crockett S.D., Bright S.D. et al. Randomised clinical trial: high-dose acid suppression for chronic cough – a double-blind, placebo-controlled study. Aliment. Pharmacol. Ther. 2011; 33 (2): 225–234. DOI: 10.1111/j.1365-2036.2010.04511.x.

117. Giuliano C., Wilhelm S.M., Kale-Pradhan P.B. Are proton pump inhibitors associated with the development of community-acquired pneumonia? A meta-analysis. Expert Rev. Clin. Pharmacol. 2012; 5 (3): 337–344. DOI: 10.1586/ecp.12.20.

118. Moayyedi P., Leontiadis G.I. The risks of PPI therapy. Nat. Rev. Gastroenterol. Hepatol. 2012; 9 (3): 132–139. DOI: 10.1038/nrgastro.2011.272.

119. Berkhof F.F., Doornewaard-ten Hertog N.E., Uil S.M. et al. Azithromycin and cough-specific health status in patients with chronic obstructive pulmonary disease and chronic cough: a randomised controlled trial. Respir. Res. 2013; 14 (1): 125. DOI: 10.1186/1465-9921-14-125.

120. Yousaf N., Monteiro W., Parker D. et al. Long-term low-dose erythromycin in patients with unexplained chronic cough: a double-blind placebo controlled trial. Thorax. 2010; 65 (12): 1107–1110. DOI: 10.1136/thx.2010.142711.

121. Hodgson D., Anderson J., Reynolds C. et al. The effects of azithromycin in treatment-resistant cough: a randomized, double-blind, placebo-controlled trial. Chest. 2016; 149 (4): 1052–1060. DOI: 10.1016/j.chest.2015.12.036.

122. Ryan N.M., Birring S.S., Gibson P.G. Gabapentin for refractory chronic cough: a randomised, double-blind, placebo-controlled trial. Lancet. 2012; 380 (9853): 1583–1589. DOI: 10.1016/S0140-6736(12)60776-4.

123. Vertigan A.E., Kapela S.L., Ryan N.M. et al. Pregabalin and speech pathology combination therapy for refractory chronic cough: a randomized controlled trial. Chest. 2016; 149 (3): 639–648. DOI: 10.1378/chest.15-1271.

124. Zaccara G., Giovannelli F., Giorgi F.S. et al. Tolerability of new antiepileptic drugs: a network meta-analysis. Eur. J. Clin. Pharmacol. 2017; 73 (7): 811–817. DOI: 10.1007/s00228-017-2245-z.

125. Gardiner S.J., Chang A.B., Marchant J.M., Petsky H.L. Codeine versus placebo for chronic cough in children. Cochrane Database Syst. Rev. 2016; 7 (7): CD011914. DOI: 10.1002/14651858.CD011914.pub2.

126. Vertigan A.E., Theodoros D.G., Gibson P.G. Winkworth A.L. Efficacy of speech pathology management for chronic cough: a randomised placebo controlled trial of treatment efficacy. Thorax. 2006; 61 (12): 1065–1069. DOI: 10.1136/thx.2006.064337.

127. Chamberlain S., Garrod R., Birring S.S. Cough suppression therapy: does it work? Pulm. Pharmacol. Ther. 2013; 26 (5): 524–527. DOI: 10.1016/j.pupt.2013.03.012.

128. Marchant J., Masters I.B., Champion A. et al. Randomised controlled trial of amoxicillin clavulanate in children with chronic wet cough. Thorax. 2012; 67 (8): 689–693. DOI: 10.1136/thoraxjnl-2011-201506.

129. Ternesten-Hasseus E., Johansson E.L., Millqvist E. Cough reduction using capsaicin. Respir. Med. 2015; 109 (1): 27–37. DOI: 10.1016/j.rmed.2014.11.001.

130. Belvisi M.G., Birrell M.A., Wortley M.A. et al. XEN-D0501, a novel transient receptor potential vanilloid 1 antagonist, does not reduce cough in patients with refractory cough. Am. J. Respir. Crit. Care Med. 2017; 196 (10): 1255–1263. DOI: 10.1164/rccm.201704-0769OC.

131. Morice A.H. TRPA1 receptors in chronic cough. Pulm. Pharmacol. Ther. 2017; 47: 42–44. DOI: 10.1016/j.pupt.2017.05.004.

132. Abdulqawi R., Dockry R., Holt K. et al. P2X3 receptor antagonist (AF219) in refractory chronic cough: a randomised, double-blind, placebo-controlled phase 2 study. Lancet. 2015; 385 (9974): 1198–1205. DOI: 10.1016/S0140-6736(14)61255-1.

133. Smith A.D., Cowan J.O., Brassett K.P. et al. Use of exhaled nitric oxide measurements to guide treatment in chronic asthma. N. Engl. J. Med. 2005; 352 (21): 2163–2173. DOI: 10.1056/NEJMoa043596.

134. Price D.B., Buhl R., Chan A. et al. Fractional exhaled nitric oxide as a predictor of response to inhaled corticosteroids in patients with non-specific respiratory symptoms and insignificant bronchodilator reversibility: a randomised controlled trial. Lancet. Respir. Med. 2018; 6 (1): 29–39. DOI: 10.1016/S2213-2600(17)30424-1.

135. Cheng S.L. Blood eosinophils and inhaled corticosteroids in patients with COPD: systematic review and meta-analysis. Int. J. Chron. Obstruct. Pulmon. Dis. 2018; 13: 2775–2784. DOI: 10.2147/COPD.S175017.

136. Mertens V., Blondeau K., Pauwels A. et al. Azithromycin reduces gastroesophageal reflux and aspiration in lung transplant recipients. Dig. Dis. Sci. 2009; 54 (5): 972–979. DOI: 10.1007/s10620-009-0725-4.